Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

BEIJING & ALAMEDA, Calif. & TAIPEI -- Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. Read More

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Transaction in Own Shares
Trian Issues Open Letter to Solventum Shareholders

Ascendant Announces Leadership Transition: Shemina Jiwani Appointed as CEO
Oil Companies Offer Zero Bids for Arctic Refuge Drilling Rights